HCA Healthcare Price Target Boosted by B of A Securities

B of A Securities raised HCA Healthcare's price target from $375 to $410, a 9.33% increase, while maintaining a "Neutral" rating. This update comes as part of recent analyst actions concerning HCA Healthcare. The average target price for HCA is $393.57, with a high estimate of $444 and a low estimate of $316.45, indicating a 1.46% upside from the current price of $387.92. The average brokerage recommendation is 2.3, indicating an "Outperform" status. The estimated GF Value for HCA in one year is $411.57, suggesting a 6.1% upside from the current price.

HCA Holdings Inc. (NYSE: HCA) has seen its stock price reach an all-time high of $417.39, reflecting strong financial performance and positive analyst sentiment. The healthcare services company has maintained a "GREAT" overall financial health score of 3.25 out of 5, according to InvestingPro data. Over the past year, HCA has shown a 7.42% change in stock price, with a 37.7% year-to-date return and consistent dividend growth of 9.1%. Management has been actively buying back shares, and 14 analysts have recently revised their earnings estimates upward.

In the second quarter of 2025, HCA reported strong financial results, exceeding earnings and revenue forecasts. Earnings per share were $6.84, surpassing expectations of $6.27, and revenue reached $18.61 billion, exceeding projections of $18.49 billion. Bernstein raised its price target for HCA from $404 to $417, while maintaining a Market Perform rating. However, Wolfe Research downgraded HCA from Outperform to Peerperform due to concerns about long-term payer mix pressures, including Exchange pressure in 2026 and Provider Tax pressure in 2028 and beyond.

In recent analyst actions, B of A Securities raised HCA's price target from $375 to $410, a 9.33% increase, while maintaining a "Neutral" rating. The average target price for HCA is $393.57, with a high estimate of $444 and a low estimate of $316.45, indicating a 1.46% upside from the current price of $387.92. The average brokerage recommendation is 2.3, indicating an "Outperform" status. The estimated GF Value for HCA in one year is $411.57, suggesting a 6.1% upside from the current price.

HCA's strong performance and positive analyst sentiment make it a focal point for stakeholders and market analysts alike. Despite some concerns about long-term payer mix pressures, the company maintains strong fundamentals, including a 40.9% gross profit margin and $14.5 billion in EBITDA over the last twelve months. As HCA continues to navigate the evolving healthcare landscape, its stock performance will remain a key indicator for investors and financial professionals.